TScan Therapeutics EPS TCRX

Diluted earnings per share by quarter and over the last twelve months, from 2020.

TScan Therapeutics' earnings per share was −$0.91 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.23.

Earnings per share over time

Each fiscal year is the twelve months to its fourth quarter.

Quarter	Ended	EPS	On a year earlier	Last 12 months
Q2 FY26	Jun 30, 2026	−$0.23	n/a	−$0.91
Q1 FY26	Mar 31, 2026	−$0.22	n/a	−$0.96
Q4 FY25	Dec 31, 2025	−$0.18	n/a	−$1.00
Q3 FY25	Sep 30, 2025	−$0.28	n/a	−$1.12
Q2 FY25	Jun 30, 2025	−$0.28	n/a	−$1.09
Q1 FY25	Mar 31, 2025	−$0.26	n/a	−$1.09
Q4 FY24	Dec 31, 2024	−$0.30	n/a	−$1.15
Q3 FY24	Sep 30, 2024	−$0.25	n/a	−$1.06
Q2 FY24	Jun 30, 2024	−$0.28	n/a	−$1.05
Q1 FY24	Mar 31, 2024	−$0.32	n/a	−$1.28
Q4 FY23	Dec 31, 2023	−$0.21	n/a	−$1.89
Q3 FY23	Sep 30, 2023	−$0.24	n/a	−$2.46

Companies in Healthcare nearest TScan Therapeutics' size, closest first, today.

Company	EPS, 12 months	Growth
TCRXTScan Therapeutics	−$0.91
NEPHNephros	$0.16	+33% a year
ATNMActinium Pharmaceuticals	$0.36
APTAlpha Pro Tech	$0.41	+24% a year
SPROSpero Therapeutics	$0.11
LFVNLifevantage	$0.40	−46% a year
ICCCImmucell	$0.08	−58% a year
KEQUKewaunee Scientific	$2.76	−33% a year
Peer median	$0.36

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.